Australia
Austria
Belgium
China
Czech Republic
Denmark
Estonia
Finland
France
Germany
Hungary
India
Ireland
Italy
Japan
Kazakhstan
Latvia
Lithuania
Malaysia
Netherlands
Norway
Poland
Singapore
Slovenia
Spain
Sweden
Thailand
UK
Ukraine
Kaisa Tarkkanen, M.Sc. (Econ.) has been appointed as President of Orion Diagnostica Oy, a subsidiary of Orion Corporation, effective October 1, 2015. Kaisa Tarkkanen has worked in Orion since 2000 in various specialist and managerial positions, last nine years as the Head of Region Scandinavia in the line Global Sales, responsible for the sales of human pharmaceuticals in Orion.
The current President of Orion Diagnostica Jaakko Rissanen will move on outside of Orion Group.
"I want to thank Jaakko Rissanen for his long career in Orion Diagnostica. He has successfully developed the business of Orion Diagnostica profitably in international and challenging markets", says Timo Lappalainen, the President and CEO of Orion Corporation and the Chairman of the Board of Orion Diagnostica.
"I welcome Kaisa Tarkkanen to Orion Diagnostica and wish her success in the new position. I trust that with Kaisa's leadership Orion Diagnostica will favourably continue building well-being also in the future", Timo Lappalainen comments.
Orion Diagnostica is specialized in development, manufacturing and marketing of diagnostic and hygiene tests for global markets.
Contact person:
Timo Lappalainen
President and CEO, Orion Corporation
Chairman of the Board of Orion Diagnostica Oy
Tel +358 50 966 3692
Published by:
Orion Corporation
Communications
Orionintie 1A, 02200 Espoo
www.orion.fi
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion develops inhaled Easyhaler® pulmonary drugs.
Orion's net sales in 2014 amounted to EUR 1,015 million and the Company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ Helsinki.
